Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues - Hallo friendsTHE LEK NEWS, In the article you read this time with the title Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article culture, Article economy, Article health, Article healthy tips, Article news, Article politics, Article sports, We write this you can understand. Alright, good read.

Title : Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues
link : Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues

Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues

Ann Gastroenterol. 2018 May-Jun;31(3):365-370. doi: 10.20524/aog.2018.0255. Epub 2018 Mar 28.

Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues.
Papadopoulos N1, Papavdi M2, Pavlidou A1, Konstantinou D2, Kranidioti H2, Kontos G2, Koskinas J2, Papatheodoridis GV3, Manolakopoulos S2, Deutsch M2.

Full-Text

Download Original Article

View Online

Abstract

Background:
Only limited data concerning hepatitis B (HBV) and C viruses (HCV) coinfection are available. Direct-acting antivirals (DAAs) may be more effective for HCV clearance than interferon (IFN)-based regimens with a risk of HBV reactivation.

Methods:
We retrospectively enrolled 40 HBV/HCV-coinfected patients to evaluate their clinical profile and treatment outcomes.

Results:
Chronic dual infection was present in 25/40 (62.5%) patients, acute HCV superinfection in 5/40 (12.5%) patients and acute HBV superinfection in 10/40 (25%). Twenty-five patients (62.5%) were treated: 16/25 (64%) with IFN, 4/25 (16%) with nucleot(s)ide analogs (NUCs) and 5/25 (20%) with DAAs. Of the 16 patients treated with IFN-based therapy, 6 (37.5%) achieved both sustained virological response (SVR) and HBsAg clearance. Of the 4 patients treated with NUCs, one (25%) achieved both SVR and HBsAg clearance. All five patients treated with DAAs (100%) achieved SVR, while one case of HBV reactivation was recorded. Fifteen of the 40 patients (37.5%) did not receive any treatment. Eight of them (53.5%) presented with acute HBV superinfection: spontaneous HCV clearance was recorded in 5/8 (62.5%), while HBsAg clearance occurred in 6/8 (75%). Three of them (20%) presented with acute HCV superinfection; spontaneous HCV clearance was recorded in one of the three (33.5%). The other four patients (26.5%) presented with dual HBV/HCV infection.

Conclusions:
A significant proportion of patients presented with active HBV replication. Treatment with DAAs seems to be efficacious for HCV eradication. However, clinicians should be aware of HBV reactivation. HBV superinfection may lead to both HBsAg and HCV clearance.

Continue to complete article: View Online

Thus Article Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues

That's an article Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues with the link address https://theleknews.blogspot.com/2018/05/hepatitis-b-and-c-coinfection-in-real.html

Tweet

Subscribe to receive free email updates: